immunoglobulin B

08/01/2020 - "Although ESG and IGB are safe and effective for weight loss, our study suggests that ESG results in more significant and sustained weight loss. "
01/01/2017 - "At M6, weight loss was significantly greater in the IGB group than in the SMC group (P < 0.0001). "
01/01/2021 - "IGB delivers weight loss to 2 years and is superior to control. "
10/01/2017 - "Several studies conducted in adults suggest that intragastric balloon (IGB) is an effective and safe method for weight loss. "
04/01/2020 - "Our results underline that IGB treatment in elderly patients is safe and effective in terms of weight loss and improvement in comorbidities. "

01/01/2019 - "The present study suggests that IGB treatment during 6 months in individuals with obesity is effective for decreasing total and central body adiposity being associated with reduction in energy intake, increase in physical activity, and improvement in quality of life."
08/01/2017 - "The aim of this study is to compare the efficacy of IGB in patients with different degrees of obesity. "
08/01/2021 - "The aim of this study was to evaluate the changes in fat mass in Korean women with obesity who had undergone IGB treatment for 6 mon. "
08/01/2020 - "Bibliographic databases were systematically searched for studies investigating the use of IGB and ESG for the treatment of obesity. "
01/01/2020 - "This proof of concept animal study was aimed to assess the feasibility, safety, efficacy, and impact on gastrointestinal physiology of combined intragastric balloons (IGB) and duodenal-jejunal bypass liner (DJBL) for the treatment of obesity. "

02/01/2009 - "IGB and LAGB are safe and effective treatments for Japanease patients with morbid obesity."
09/01/2001 - "This study evaluated the effectiveness and safety of an intragastric balloon (IGB) for the treatment of morbid obesity. "
01/01/2022 - "Endoscopic intragastric balloon (IGB) placement is a minimally invasive treatment for morbid obesity that is sometimes used as a preparatory step before surgical intervention. "
09/01/2021 - "Twenty five patients with morbid obesity (OB, 43.9 ± 11.8 years, BMI = 49.1 ± 7.2, 12 females, 9 without co-morbid conditions) were treated with IGB for six months. "
11/01/2017 - "Intragastric balloon (IGB) insertion has been most frequently used in the West as an effective endoscopic treatment for morbid obesity, in practice. "

12/01/2020 - "Endoscopic IGB treatment for excess weight is an excellent therapeutic option for patients with different degrees of overweight."
09/01/2018 - "After temporary IGB implantation in overweight or obese individuals, a WL that was ≥10% of weight at baseline was achieved in 54.3% and sustained at 6-12 months in 41.4% of participants. "
01/01/2018 - "The aim is to evaluate the effects of IGB in overweight or class I obese patients, by analyzing body composition and quality of life (QOL). "
01/01/2016 - "IGB time was 190 ± 36 d in the overweight patients and 192 ± 43 d in the obese patients. "
01/01/2016 - "Twenty-six overweight [body mass index (BMI), 26-30)] and 113 obese (BMI > 30) patients underwent outpatient, endoscopic IGB placement under intravenous sedation. "

10/24/2017 - "The aim of this study was to investigate the effect of 6 months of treatment with an intragastric balloon (IGB) on health-related quality of life (HRQOL) and its relation to changes in body fat in obese individuals with metabolic syndrome (MS). "
01/01/2016 - "The aim of this study was to investigate the effects of a 6-month treatment with intragastric balloon (IGB) on body composition and depressive/anxiety symptoms in obese individuals with metabolic syndrome (MS). "
08/01/2013 - "This randomized, controlled study evaluated the efficacy and safety of an IGB in obese individuals with metabolic syndrome (MS). "
04/01/2019 - "Forty obese patients with metabolic syndrome (mean age 35.1 ± 7.3 yr) used an IGB continuously for 6 mo. Laboratory tests, areal BMD, and body composition measurements via dual-energy X-ray absorptiometry, and volumetric BMD and bone microstructure measurements via high-resolution peripheral quantitative computed tomography were conducted before IGB placement and after IGB removal. "
06/01/2014 - "Due to improvement of metabolic parameters and substantial benefit on liver function, obese people with metabolic syndrome appear to be the best candidates for IGB placement. "